A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

NCT05200312 ↗

Phase 2 Unknown 36 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line therapy for treatment-naive high-risk diffuse large B-cell lymphoma patients.

Timeline

Start: 2022-02-01
Primary completion: 2024-02-01
Completion: 2025-02-01

Publications

Xia Y, Miao Y, Qian S, Zhang R, Qin S, Xie X, Li B, Sha Y, Tang H, Jin H, Cao L, Xu W, Fan L, Li J, Shi W, Zhu H. Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG). BMC Med. 2025 Oct 24;23(1):583. doi: 10.1186/s12916-025-04418-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Subject	Prednisone	Other / unclassified	40 mg/m2	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous
Subject	Zanubrutinib	Small molecule	160 mg	Oral

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications